AUS Edition 
NZ Edition 
UK Edition 
CA Edition 
USA Edition 
IND Edition 
⚠
✓
PTC Therapeutics Inc (NASDAQ:PTCT)
68.68 USD
+0.450 0.660%Sponsored Reports
Loading...
| Previous Close (in USD) | 68.23 |
|---|---|
| Change | +0.450 0.660% |
| 52 W H/L (in USD) | 45.680/17.530 |
| EBITDA (in USD) | -30.58M |
| PE Ratio | -- |
| Volume | 1116366 |
| Diluted Eps TTM | -7.69 |
| Total Assets (in USD) | 1903.181M |
|---|---|
| Total Liabilities (in USD) | 2721.736M |
| Revenue TTM (in USD) | 927.558M |
| Cash (in USD) | 594.001M |
| Market Cap (in USD) | 2,797.132 M |
| Revenue Per Share TTM | 12.281 |
| Gross Profit TTM (in USD) | 2.627M |
Summary
Income Statement
Balance Sheet
Change in Cash
Operating Cash
PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children. Its development pipeline products include Sepiapterin for the treatment of phenylketonuria; PTC518 splicing platform, which is being developed for the treatment of Huntington's disease; and ferroptosis and inflammation platforms, including vatiquinone to treat Friedreich ataxia and utreloxastat for the treatment of amyotrophic lateral sclerosis. The company distributes its products through third-party distributors. It has collaborations with F. Hoffman-La Roche Ltd, Hoffman-La Roche Inc., the SMA Foundation, National Taiwan University, Akcea Therapeutics, Inc., and Shiratori Pharmaceutical Co., Ltd. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
Employees: 988
Key Executives
| Sr. No. | Name | Title | Year Born |
|---|---|---|---|
| 1. | Dr. Stuart W. Peltz Ph.D. | Co-Founder, CEO & Exec. Director | 1960 |
| 2. | Dr. Allan Steven Jacobson Ph.D. | Co-Founder, Chairman of Scientific Advisory Board & Independent Director | 1946 |
| 3. | Ms. Emily Luisa Hill | Chief Financial Officer | 1980 |
| 4. | Dr. Neil Almstead Ph.D. | Chief Technical Operations Officer | 1967 |
| 5. | Mr. Mark Elliott Boulding | Exec. VP & Chief Legal Officer | 1961 |
| 6. | Mr. Eric Pauwels | Chief Bus. Officer | 1961 |
| 7. | Ms. Dawn A. Svoronos | Advisor | 1953 |
| 8. | Dr. Matthew B. Klein F.A.C.S., FACS, M.D., M.S., MS | Chief Operating Officer | 1972 |
| 9. | Ms. Christine Utter | Sr. VP, Chief Accounting Officer & Head of People Services | 1978 |
| 10. | Ms. Ellen Welch Ph.D. | Chief Scientific Officer | NA |
Peers
Sector: Healthcare
Industry: Biotechnology
| Company | Change (USD) | Price (USD) | Trailing PE(x) | Forward PE(x) | Price Sales TTM(x) | Price to Book Value(x) | Enterprise Value to Revenue(x) | Enterprise Value to EBITDA(x) |
|
NVO
Novo Nordisk A/S |
-0.920 2.144% | 42.715 | 41.580 | 31.153 | 2.134 | 32.989 | 2.113 | 4.700 |
|
NONOF
Novo Nordisk A/S |
-0.750 1.734% | 42.5 | 41.060 | 31.250 | 2.078 | 33.111 | 2.113 | 4.700 |
|
VRTX
Vertex Pharmaceuticals Inc |
+3.250 0.765% | 420.63 | 29.670 | 24.331 | 10.385 | 5.832 | 9.334 | 20.004 |
|
REGN
Regeneron Pharmaceuticals Inc |
+16.030 2.659% | 600.79 | 29.070 | 20.121 | 7.570 | 3.823 | 6.950 | 19.423 |
Income Statement
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Income Before Tax | -587.487M | -518.34M | -402.932M | -239.926M | -128.11M |
| Minority Interest | - | - | - | - | - |
| Net Income | -559.017M | -523.901M | -438.16M | -251.576M | -128.081M |
| Selling General Administrative | 300.098M | 285.273M | 245.164M | 202.541M | 153.548M |
| Gross Profit | 654.123M | 506.265M | 361.824M | 294.845M | 252.064M |
| Reconciled Depreciation | 128.836M | 64.134M | 43.49M | 32.18M | 26.087M |
| Ebit | -439.925M | -374.943M | -397.875M | -192.798M | -77.005M |
| Ebitda | -372.578M | -378.067M | -227.815M | -116.788M | -54.128M |
| Depreciation And Amortization | 67.347M | -3.124M | 170.06M | 76.01M | 22.877M |
| Operating Income | -439.925M | -374.943M | -397.875M | -192.798M | -115.685M |
| Other Operating Expenses | 1138.726M | 913.536M | 778.641M | 499.778M | 361.079M |
| Interest Expense | 90.871M | 86.022M | 56.352M | 12.491M | 12.554M |
| Tax Provision | -28.47M | 5.561M | 35.228M | 11.65M | -0.029M |
| Interest Income | - | - | - | 12.491M | 12.554M |
| Net Interest Income | -90.871M | -86.022M | -56.352M | -12.491M | -12.554M |
| Income Tax Expense | -28.47M | 5.561M | 35.228M | 11.65M | -0.029M |
| Total Revenue | 698.801M | 538.593M | 380.766M | 306.98M | 264.734M |
| Total Operating Expenses | 1094.048M | 881.208M | 759.699M | 487.643M | 348.409M |
| Cost Of Revenue | 44.678M | 32.328M | 18.942M | 12.135M | 12.67M |
| Total Other Income Expense Net | -147.562M | -143.397M | -5.057M | -47.128M | -19.211M |
| Net Income From Continuing Ops | -559.017M | -523.901M | -438.16M | -251.576M | -128.081M |
| Net Income Applicable To Common Shares | -559.017M | -523.901M | -438.16M | -251.576M | -128.081M |
Balance Sheet
(Currency in USD)| Breakdown | 31-12-2023 | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 |
|---|---|---|---|---|---|
| Total Assets | 1903.181M | 1705.619M | 1938.056M | 2208.278M | 1623.782M |
| Intangible Assets | 379.497M | 705.891M | 724.841M | 715.328M | 710.5M |
| Other Current Assets | 150.291M | 105.658M | -126.311M | 39.469M | 17.898M |
| Total Liab | 2721.736M | 2052.705M | 1936.618M | 1726.296M | 1029.452M |
| Total Stockholder Equity | -818.555M | -347.086M | 1.438M | 481.982M | 594.33M |
| Other Current Liab | 580.252M | 365.247M | 60.751M | 245.776M | 197.291M |
| Common Stock | 0.075M | 0.072M | 0.071M | 0.07M | 0.062M |
| Capital Stock | 0.075M | 0.072M | 0.071M | 0.07M | 0.062M |
| Retained Earnings | -3283.578M | -2656.974M | -2097.957M | -1628.877M | -1190.499M |
| Good Will | 82.341M | 82.341M | 82.341M | 82.341M | 82.341M |
| Other Assets | - | 33.382M | 46.5M | 60.623M | 16.415M |
| Cash | 594.001M | 410.705M | 773.376M | 208.812M | 686.563M |
| Cash And Equivalents | - | - | - | - | - |
| Total Current Liabilities | 603.1M | 406.236M | 509.348M | 277.333M | 235.857M |
| Current Deferred Revenue | 0.801M | 1.351M | 265.751M | 4.151M | 8.242M |
| Net Debt | -178.975M | 292.922M | -341.942M | 211.626M | -372.704M |
| Short Term Debt | 16.002M | 12.37M | 159.813M | 8.741M | 20M |
| Short Long Term Debt | 194.314M | - | 149.54M | - | 20M |
| Short Long Term Debt Total | 415.026M | 703.627M | 431.434M | 420.438M | 313.859M |
| Other Stockholder Equity | 2466.233M | 2305.02M | 2123.606M | 2171.746M | 1795.351M |
| Property Plant Equipment | - | 72.59M | 130.006M | 33.831M | 21.549M |
| Total Current Assets | 1218.629M | 693.785M | 773.376M | 1231.745M | 779.284M |
| Long Term Investments | - | - | - | - | - |
| Short Term Investments | 282.738M | 130.871M | 583.658M | 894.838M | 398.535M |
| Net Receivables | 161.022M | 155.614M | 110.455M | 69.929M | 55.538M |
| Long Term Debt | 1903.996M | 571.722M | 281.894M | 309.145M | 293.859M |
| Inventory | 30.577M | 21.808M | 15.856M | 18.697M | 19.285M |
| Accounts Payable | 6.045M | 27.268M | 23.033M | 18.665M | 10.324M |
| Accumulated Other Comprehensive Income | -1.285M | 4.796M | -24.282M | -60.957M | -10.584M |
| Non Currrent Assets Other | 19.963M | 48.582M | 227.492M | 60.623M | 30.108M |
| Non Current Assets Total | 684.552M | 1011.834M | 1164.68M | 976.533M | 844.498M |
| Capital Lease Obligations | 130.813M | 131.905M | 103.945M | 111.293M | - |
| Long Term Debt Total | - | 571.722M | 281.894M | 309.145M | 293.859M |
Cash Flow
(Currency in USD)| Breakdown | 31-12-2022 | 31-12-2021 | 31-12-2020 | 31-12-2019 | 31-12-2018 |
|---|---|---|---|---|---|
| Investments | 442.641M | 304.513M | -505.571M | -341.798M | 21.809M |
| Total Cashflows From Investing Activities | 290.181M | 219.182M | -561.548M | -387.237M | -42.613M |
| Total Cash From Financing Activities | 167.952M | 20.877M | 668.715M | 613.209M | 131.571M |
| Net Income | -559.017M | -523.901M | -438.16M | -251.576M | -128.081M |
| Change In Cash | 98.707M | -19.094M | -79.216M | 126.03M | 57.706M |
| Begin Period Cash Flow | 197.218M | 216.312M | 295.528M | 169.498M | 111.792M |
| End Period Cash Flow | 295.925M | 197.218M | 216.312M | 295.528M | 169.498M |
| Total Cash From Operating Activities | -356.654M | -251.332M | -194.071M | -98.639M | -27.641M |
| Depreciation | 128.836M | 64.134M | 84.872M | 32.18M | 26.087M |
| Other Cashflows From Investing Activities | -120.444M | -57.118M | -38.134M | -31.682M | -57.325M |
| Dividends Paid | - | - | - | - | - |
| Change To Inventory | -6.668M | 1.8M | 1.841M | -3.456M | -5.823M |
| Sale Purchase Of Stock | 71.082M | 23.101M | 103.574M | 345.609M | 131.571M |
| Other Cashflows From Financing Activities | 269.228M | 23.101M | 686.785M | 301.12M | 13.655M |
| Capital Expenditures | 152.46M | 85.331M | 55.977M | 45.439M | 15.53M |
| Change In Working Capital | -85.335M | -23.788M | 36.911M | 20.427M | 14.209M |
| Other Non Cash Items | 82.805M | 128.333M | 46.109M | 49.367M | 27.382M |
| Free Cash Flow | -509.114M | -336.663M | -250.048M | -144.078M | -43.171M |
Funds
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Vanguard Health Care Inv | 2 years ago | 3393863 |
| 2. | Vanguard Total Stock Mkt Idx Inv | 2 years ago | 2365091 |
| 3. | SPDR® S&P Biotech ETF | 2 years ago | 2285041 |
| 4. | Vanguard Small Cap Index | 2 years ago | 1919290 |
| 5. | Hartford MidCap Y | 2 years ago | 1891233 |
| 6. | iShares Russell 2000 ETF | 2 years ago | 1683133 |
| 7. | Vanguard Institutional Extnd Mkt Idx Tr | 2 years ago | 1128362 |
| 8. | Janus Henderson Global Life Sciences D | 2 years ago | 1106977 |
| 9. | Janus Henderson Global Life Sciences | 2 years ago | 1106977 |
| 10. | Vanguard Small Cap Growth Index Inv | 2 years ago | 1084555 |
| 11. | Franklin Biotechnology Discv A(acc)USD | 2 years ago | 901831 |
| 12. | Janus Selection Global Life Science AUSD | 2 years ago | 837409 |
| 13. | Janus Henderson Glb Life Scn I2 USD | 2 years ago | 837409 |
| 14. | Vanguard Strategic Equity Inv | 2 years ago | 814425 |
| 15. | Fidelity Select Biotechnology | 2 years ago | 735911 |
| 16. | Fidelity Small Cap Index | 2 years ago | 735027 |
| 17. | Vanguard Explorer Inv | 2 years ago | 638054 |
| 18. | iShares Biotechnology ETF | 2 years ago | 537035 |
| 19. | iShares Russell 2000 Growth ETF | 2 years ago | 490744 |
| 20. | Franklin Biotechnology Discovery A | 2 years ago | 480611 |
Institutions
| Sr. No. | Name | Purchased On | Shares |
|---|---|---|---|
| 1. | Wellington Management Company LLP | 2 years ago | 9816603 |
| 2. | Vanguard Group Inc | 2 years ago | 9369014 |
| 3. | BlackRock Inc | 2 years ago | 7634122 |
| 4. | RTW INVESTMENTS, LLC | 2 years ago | 7423970 |
| 5. | Armistice Capital, LLC | 2 years ago | 6764000 |
| 6. | State Street Corporation | 2 years ago | 4633955 |
| 7. | Camber Capital Management LLC | 2 years ago | 4000000 |
| 8. | COWEN AND COMPANY, LLC | 2 years ago | 3725626 |
| 9. | HHG PLC | 2 years ago | 3669816 |
| 10. | FMR Inc | 2 years ago | 1814421 |
| 11. | Geode Capital Management, LLC | 2 years ago | 1611225 |
| 12. | Jacobs Levy Equity Management, Inc. | 2 years ago | 1605841 |
| 13. | Franklin Resources Inc | 2 years ago | 1426378 |
| 14. | Adage Capital Partners Gp LLC | 2 years ago | 1270000 |
| 15. | Morgan Stanley - Brokerage Accounts | 2 years ago | 1246259 |
| 16. | D. E. Shaw & Co LP | 2 years ago | 1225748 |
| 17. | Blackstone Inc | 2 years ago | 1095290 |
| 18. | Goldman Sachs Group Inc | 2 years ago | 1052988 |
| 19. | Pictet Asset Manangement SA | 2 years ago | 826076 |
| 20. | JANE STREET GROUP, LLC | 2 years ago | 817858 |
Data Powered by EOD Historical Data (“EODHD”). All CFDs (stocks, indices, mutual funds, ETFs), and Forex are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. EODHD is not using exchanges data feeds for the pricing data, EODHD is using OTC, peer to peertrades and trading platforms over 100+ sources, EODHD is aggregating its data feeds via VWAP method. Therefore, EOD Historical Data doesn’t bear any responsibility for any trading losses you might incur as a result of using this data. EOD Historical Data or anyone involved with EOD Historical Data will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. EOD Historical Data does not give any warranties (including, without limitation, as to merchantability or fitness for a particular purpose or use).
Sponsored Articles
Loading...
Related Articles
Loading...